TUCSON, AZ / ACCESS Newswire / April 29, 2025 / Retatrutide, also known as LY3437943, is an innovative triple receptor agonist targeting glucose-dependent insulinotropic polypeptide (GIP), ...

Drugs that bind to and activate the receptors for the hormones GLP-1 and GIP are effective in the treatment of obesity and ...

In a joint venture with Novo Nordisk, Hims & Hers will dispense all doses of Wegovy to Americans who buy eligible subscriptions, with plans starting at $599 a month. The offering ...

Objective: To review drug interaction studies of glucagon-like peptide-1 receptor agonists ... target peak concentrations or a rapid onset of action. Studies in patients with type 2 diabetes ...

TNF Pharmaceuticals and Renova Health are set to use AI and machine learning for the identification of high-risk subjects who ...

DA-1726 is a novel oxyntomodulin (OXM) analogue that functions as a glucagon-like peptide-1 receptor (GLP1R ... DA-1241 demonstrated direct hepatic action in addition to its glucose lowering ...

Mochi Health, one of those implicated, is one of the largest telehealth providers of compounded GLP-1RAs. Eli Lilly maintains ...

Leveraging AI, researchers have identified a naturally occurring molecule that can suppress appetite and facilitate weight loss in mice and pigs.

Lilly said the drug, orforglipron, had a safety profile consistent with similar approved glucagon-like peptide-1 (GLP-1 ... drug trial of a promising dual action obesity medication which showed ...

Ascletis's news arrives shortly after Eli Lilly reported favourable Phase III weight loss data for its oral GLP-1RA, ...

Researchers at the Pennington Biomedical Research Center conducted a first-of-its-kind study to provide insights into the mechanisms of action of tirzepatide—a drug known as Zepbound—on weight loss ...